Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

Inclusion Criteria: * Age \>= 18 years; * Visual acuity letter score in study eye \< 70 and ≥ 25 letters (approximate Snellen equivalent 20/32 to 20/320); * Ophthalmoscopic evidence of center-involved macular edema, within the central subfield (CSF); • Inflammatory disorders of the sclera, choroid, retina or vitreous Exclusion Criteria: * Inability to understand informed consent, cooperate with testing or return to follow up visits; * Pregnant or lactating women; * Co-existent ocular disorder of the cornea, lens or media that will interfere with assessment of safety or efficacy.